New antihypertensive targets difficult-to-treat patients

Patients who are not managed properly on oral blood pressure medications have a new option available to them. It's Medicines Co.'s Cleviprex (clevidipine butyrate), the first new IV antihypertensive treatment approved in 10 years. According to the Parsippany, N.J., firm, the drug is metabolized in the blood and tissues, rather than in the kidney or liver, so it does not accumulate in the body. Moreover this latest-generation IV dihydropyridine calcium channel blocker works rapidly and can be titrated precisely for use in the acute care setting.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, clickhere.